Document and Entity Information Document Information [Table] Entity Addresses, Address Type [Axis] Address Type [Domain] Business Contact [Member] Business Contact Document Information [Line Items] Document and Entity Information Document Type Document Registration Statement Document Annual Report Document Period End Date Current Fiscal Year End Date Document Fiscal Year Focus Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Primary SIC Number Entity Tax Identification Number Contact Personnel Name Entity Address, Address Line One Entity Address, Adress Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address State Or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Annual Information Form Audited Annual Financial Statements Entity Common Stock, Shares Outstanding Entity Current Reporting Status Entity Interactive Data Current Entity Emerging Growth Company Entity Ex Transition Period ICFR Auditor Attestation Flag Document Financial Statement Error Correction [Flag] Auditor Name Auditor Location Auditor Firm ID Entity Central Index Key Document Fiscal Period Focus Amendment Flag Consolidated Statements of Financial Position Schedule disclosing information related to financial position. Statement Of Financial Position [Table] Statement Of Financial Position [Table] Assets and liabilities classified as held for sale [axis] Assets and liabilities not classified as held for sale [member] Non-current assets held for sale [member] Assets held for sale Intangible assets other than goodwill [member] Intangible asset Equity investments [member] Investments Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. Statement Of Financial Position [Line Items] Consolidated Statements of Financial Position Assets [abstract] ASSETS Current assets [abstract] Current Cash and cash equivalents. CASH AND CASH EQUIVALENTS - End of year CASH AND CASH EQUIVALENTS - Beginning of year Cash and cash equivalents Total cash and cash equivalents Current investments Guaranteed Investment Certificates Short-term investments The amount of current trade receivables and current other receivables excluding prepayments. Trade And Other Current Receivables Excluding Prepayments Sales tax, interest and other receivables Current prepayments Prepaid expenses and deposits Total prepaid expenses and deposits Current derivative financial assets Derivative financial instruments, net Current assets Total current assets Property, plant and equipment Property and equipment Non-current assets or disposal groups classified as held for sale Assets held for sale Non-current assets Total non-current assets Assets Total assets TOTAL ASSETS Liabilities [abstract] LIABILITIES Trade and other current payables Accounts payable and accrued liabilities Total accounts payable and accrued liabilities Current liabilities Total current liabilities Liabilities Total Liabilities Equity [abstract] SHAREHOLDERS' EQUITY Issued capital Common Shares Warrant reserve Pre-Funded Warrants Additional paid-in capital Contributed surplus Retained earnings Accumulated deficit Accumulated other comprehensive income Accumulated other comprehensive income/(loss) Equity Balance - at end Balance - at beginning (Notes 2 and 19) Total shareholders' equity Equity and liabilities TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY Consolidated Statements of Loss and Comprehensive Loss Research and development expense Research and development ("R&D") General and administrative expense General and administrative ("G&A") Profit (loss) from operating activities TOTAL OPERATING EXPENSES: No definition available. IFRS Nonoperating Income (Expense) [Abstract] OTHER INCOME AND EXPENSES Finance income Finance income Impairment loss recognised in profit or loss, intangible assets other than goodwill Impairment of intangible asset Impairment of intangible asset Losses on change in fair value of derivatives Loss on derivative financial instruments Foreign exchange gain Foreign exchange gain Profit (loss) before tax NET LOSS BEFORE INCOME TAXES Tax expense (income) Income tax expense Tax expense/(recovery) Profit (loss) Net loss for the year NET LOSS FOR THE YEAR Other comprehensive income [abstract] OTHER COMPREHENSIVE LOSS Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract] Item that may be reclassified to net loss Other comprehensive income, net of tax, exchange differences on translation of foreign operations Foreign currency translation adjustment Comprehensive income TOTAL COMPREHENSIVE LOSS Basic earnings (loss) per share Basic loss per Common Share (in dollars per share) Diluted earnings (loss) per share Diluted loss per Common Share (in dollars per share) The amount of profit (loss) attributable to Pre-Funded warrant holders of the parent entity (the numerator) divided by the weighted average number of Pre-Funded warrant outstanding during the period (the denominator). Pre-Funded Warrant, Earnings (Loss) Per Share Basic Basic loss per Pre-Funded Warrant (in dollars per share) The amount of profit (loss) attributable to Pre-Funded warrant of the parent entity (the numerator), divided by the weighted average number of Pre-Funded warrant outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential Pre-Funded warrant. Pre-Funded Warrant, Earnings (Loss) Per Share Diluted Diluted loss per Pre-Funded Warrant (in dollars per share) Weighted average number of ordinary shares used in calculating basic earnings per share Weighted average number of Common Shares, basic (in shares) Weighted average number of ordinary shares used in calculating diluted earnings per share Weighted average number of Common Shares, diluted (in shares) Consolidated Statements of Changes in Shareholders' Equity Statement of changes in equity [table] Components of equity [axis] Components of equity [domain] Issued capital [member] Common Shares Warrant reserve [member] Pre-Funded Warrants Additional paid-in capital [member] Contributed Surplus Retained earnings [member] Accumulated Deficit Accumulated other comprehensive income [member] Accumulated Other Comprehensive Loss Statement of changes in equity [line items] Consolidated Statements of Changes in Shareholders' Equity Changes in equity [abstract] Consolidated Statements of Changes in Shareholders' Equity Number of shares outstanding Balance - at end (in shares) Balance - at beginning (in shares) (Notes 2 and 19) Common Shares Number of shares issued in connection with exercise of warrants. Stock Issued During Period, Shares, Warrants Exercised Exercise of warrants (in shares) (Note 9) Increase (decrease) through exercise of warrants, equity Exercise of warrants (Note 9) Number of new stock issued during the period. IFRS Stock Issued During Period, Shares, New Issues Equity issued in equity offering, net of transaction costs (in shares) Issue of equity Equity issued in equity offering, net of transaction costs Number of shares issued in exchange of warrants other than those resulting from share-based payment arrangements. Issuance Of Shares In Connection With Exercise Of Warrants Common Shares issued in connection with the exercise of Pre-Funded Warrants (in shares) (Note 8) Amount of shares issued in exchange of warrants other than those resulting from share-based payment arrangements. Issuance Of Shares In Connection With Exercise Of Warrants, Value Common Shares issued in connection with the exercise of Pre-Funded Warrants (Note 8) Number of shares issued in connection with exercise of stock options. IFRS Stock Issued During Period, Shares, Stock Options Exercised Common Shares issued upon exercise of stock options (in shares) Increase (decrease) through exercise of options, equity Common Shares issued upon exercise of stock options Increase (decrease) through share-based payment transactions, equity Stock-based compensation (Note 10) Disclosure of classes of share capital [table] Non-adjusting events after reporting period [axis] Non-adjusting events after reporting period [domain] Major ordinary share transactions [member] Share transactions Disclosure of classes of share capital [line items] Share capital and Pre-Funded Warrants Warrants Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. IFRS Stockholders' Equity Note, Stock Split, Conversion Ratio Share consolidation ratio Consolidated Statements of Cash Flows Cash flows from (used in) operating activities [abstract] OPERATING ACTIVITIES Adjustments to reconcile profit (loss) [abstract] Items not affecting cash: Adjustments for depreciation expense Depreciation of property and equipment Adjustments for share-based payments Stock-based compensation Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss Impairment of intangible assets Adjustments for gains (losses) on change in fair value of derivatives Loss on derivative financial instruments Adjustments for finance income Non-cash finance income Adjustments for unrealised foreign exchange losses (gains) Unrealized foreign exchange gain Adjustments for decrease (increase) in trade and other receivables Sales tax, interest and other receivables Adjustments for decrease (increase) in prepaid expenses Prepaid expenses and deposits Adjustments for increase (decrease) in trade and other payables Accounts payable and accrued liabilities Cash flows from (used in) operating activities CASH AND CASH EQUIVALENTS PROVIDED BY (USED IN) OPERATING ACTIVITIES Cash flows from (used in) financing activities [abstract] FINANCING ACTIVITIES Proceeds from exercise of warrants Proceeds from exercise of warrants Proceeds from exercise of options Proceeds from exercise of stock options Proceeds from issuing shares Proceeds from Common Shares issuance, net of costs The cash inflow from issuance of rights to purchase common shares at predetermined price. IFRS Proceeds from Issuance of Warrants Proceeds from Pre-Funded Warrants issuance, net of costs Cash flows from (used in) financing activities CASH AND CASH EQUIVALENTS PROVIDED BY (USED IN) FINANCING ACTIVITIES Cash flows from (used in) investing activities [abstract] INVESTING ACTIVITIES Purchase of investments other than investments accounted for using equity method Purchases of short-term investments Proceeds from sales of investments other than investments accounted for using equity method Maturities of short-term investments Purchase of property, plant and equipment, classified as investing activities Purchase of property and equipment Cash flows from (used in) investing activities CASH AND CASH EQUIVALENTS PROVIDED BY (USED IN) INVESTING ACTIVITIES Effect of exchange rate changes on cash and cash equivalents Effect of foreign currency exchange rates on cash and cash equivalents Increase (decrease) in cash and cash equivalents after effect of exchange rate changes INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS Interest received, classified as operating activities Cash interest received included in operating activities No definition available. Description of business Disclosure of general information about financial statements [text block] Description of business No definition available. Basis of presentation and material accounting policies The entire disclosure for basis of presentation and material accounting policy information applied by the entity. Disclosure Of Basis Of Presentation And Material Accounting Policy Information [Text Block] Basis of presentation and material accounting policies Cash and cash equivalents Disclosure of cash and cash equivalents [text block] Cash and cash equivalents No definition available. Short-term investments Disclosure of investments other than investments accounted for using equity method [text block] Short-term investments Prepaid expenses and deposits Disclosure of prepayments and other assets [text block] Prepaid expenses and deposits No definition available. Intangible asset and assets held for sale The entire disclosure for intangible assets and assets held for sale. Disclosure Of Intangible Asset And Assets Held For Sale [Text Block] Intangible asset and assets held for sale Accounts payable and accrued liabilities Disclosure of trade and other payables [text block] Accounts payable and accrued liabilities Share capital and Pre-Funded Warrants Disclosure of share capital, reserves and other equity interest [text block] Share capital and Pre-Funded Warrants No definition available. Warrants The entire disclosure for warrant or rights. Warrants and Rights Note Disclosure [Text Block] Warrants Stock-based compensation Disclosure of share-based payment arrangements [text block] Stock-based compensation Operating expenses Disclosure of expenses by nature [text block] Operating expenses No definition available. Commitments and contingencies Disclosure of commitments and contingent liabilities [text block] Commitments and contingencies Related party transactions Disclosure of related party [text block] Related party transactions Income taxes Disclosure of income tax [text block] Income taxes Segmented information Disclosure of entity's operating segments [text block] Segmented information No definition available. Capital management Disclosure of going concern [text block] Capital management Financial instruments and risk management Disclosure of financial instruments [text block] Financial instruments and risk management Subsequent events Disclosure of events after reporting period [text block] Subsequent events No definition available. Change in presentation currency The entire disclosure for changes in presentation currency. Disclosure of Change in Presentation Currency [Text Block] Change in presentation currency Disclosure of basis of preparation of financial statements [text block] Basis of presentation The description of the entity's material accounting policy information for change in functional and presentation currency. Description Of Accounting Policy For Change In Functional And Presentation Currency [Policy Text Block] Change in functional and presentation currency Disclosure of basis of consolidation [text block] Basis of consolidation Description of accounting policy for determining components of cash and cash equivalents [text block] Cash and cash equivalents Description of accounting policy for functional currency [text block] Functional and presentation currency Description of accounting policy for income tax [text block] Current and deferred income taxes Description of accounting policy for financial instruments [text block] Financial instruments Description of accounting policy for impairment of non-financial assets [text block] Impairment of non-financial assets Description of accounting policy for intangible assets other than goodwill [text block] Intangible assets Description of accounting policy for research and development expense [text block] Research and development The description of the entity's material accounting policy information for research and development tax credits receivable. Description Of Accounting Policy For Research And Development Tax Credits Receivable [Policy Text Block] Research and development tax credits receivable Description of accounting policy for issued capital [text block] Share capital Description of accounting policy for share-based payment transactions [text block] Stock-based compensation Description of accounting policy for earnings per share [text block] Loss per share Disclosure of expected impact of initial application of new standards or interpretations [text block] New and amended standards and interpretations Disclosure of accounting judgements and estimates [text block] Use of judgements and estimates Tabular disclosure of cash and cash equivalents. Schedule Of Cash And Cash Equivalents [Text Block] Schedule of cash and cash equivalents Tabular disclosure of short-term investments. Schedule Of Short Term Investments [Table Text Block] Schedule of short-term investments Tabular disclosure of prepayments. Schedule Of Prepayments [Table Text Block] Schedule of prepaid expenses and deposits The tabular disclosure of information pertaining to trade and other payables. Schedule of Trade and Other Payables [Table Text Block] Schedule of accounts payable and accrued liabilities Disclosure of classes of share capital [text block] Schedule of effect of the share consolidation on the issued and outstanding number of Common Shares, Pre-Funded Warrants, and stock options outstanding The tabular disclosure of information pertaining to pre-funded warrants. Schedule of Pre-funded Warrants [Table Text Block] Schedule of changes in Pre-Funded Warrants Tabular disclosure of warrants or rights issued excluding pre-funded warrants. Schedule of Stockholders' Equity Note, Warrants or Rights Excluding Pre-Funded Warrants [Table Text Block] Summary of changes in warrants Disclosure of number and weighted average exercise prices of share options [text block] Schedule for stock option transactions Disclosure of range of exercise prices of outstanding share options [text block] Schedule of stock options outstanding by exercise price range Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block] Schedule of assumptions to determine the fair value of stock options granted Disclosure of attribution of expenses by nature to their function [text block] Schedule of operating expenses Disclosure of commitments [text block] Summary of commitments for research and development activities Disclosure of information about key management personnel [text block] Schedule of remuneration of key management personnel Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations. IFRS Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of reconciliation of income taxes at statutory rates with the reported taxes Disclosure of temporary difference, unused tax losses and unused tax credits [text block] Schedule of temporary differences have not been recognized Disclosure of geographical areas [text block] Schedule of non-capital loss carry forward expiration by country Disclosure of nature and extent of risks arising from financial instruments [text block] Schedule of balances held in foreign currencies, presented in US dollars The tabular disclosure for changes in presentation currency. Schedule of Change in Presentation Currency [Table Text Block] Schedule of effects of the change in presentation currency Disclosure of analysis of single amount of discontinued operations [table] Continuing and discontinued operations [axis] Continuing operations, unless line item indicates otherwise [member] Discontinued operations [member] Discontinued operations This member stands for Amphotericin B Technologies, Inc disposal group, not discontinued operations. Amphotericin B Technologies Inc Disposal Group, Not Discontinued Operations [Member] Amphotericin B Technologies, Inc disposal group, not discontinued operations Disclosure of analysis of single amount of discontinued operations [line items] Description of business Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation. Ifrs Disposal Group, Including Discontinued Operation, Consideration Consideration received The amount of total net income in basic loss per share for Pre-Funded Warrants . Net Income Net income Balances with banks Cash balances with banks Short-term investments, classified as cash equivalents Short-term instruments Schedule disclosing information related to details of short-term investment. Disclosure Of Short Term Investments [Table] Range [axis] Range [domain] Bottom of range [member] Minimum Top of range [member] Maximum Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. Disclosure Of Short Term Investments [Line Items] Short-term investments The interest rate on short-term investments. Short Term Investment, Interest Rate Interest rate Current advances to suppliers Research and development deposits Current prepaid expenses Other prepaids and deposits Disclosure of detailed information about intangible assets [table] Legal Entity [Axis] Entity [Domain] This member stands for NW Pharmatech Limited. N W Pharmatech Limited [Member] NWPT Ownership [Axis] Ownership [Domain] This member stands for NW Micelle Therapeutics Inc. N W Micelle Therapeutics Inc [Member] NWMT Disclosure of detailed information about intangible assets [line items] Intangible asset and assets held for sale Represents the number of patents licensed. Number Of Patents Licensed Number of patents licensed Percentage of ownership interest acquired in exchange for licensing technology. Percentage Of Ownership Interest Acquired Through License Exchange Ownership interest acquired through license exchange (as percent) Proportion of ownership interest in subsidiary Ownership interest (as percent) The strike price on call option. Call Option, Strike Price Call option strike price The strike price on put option. Put Option, Strike Price Put option strike price Amount of fair value of noncurrent assets held for sale. Fair Value Of Noncurrent Assets Held For Sale Fair value Current trade payables Trade payables Current financial liabilities Short-term instruments Current tax liabilities Income taxes payable Classes of share capital [axis] Classes of share capital [domain] Ordinary shares [member] Common Shares This member stands for pre-funded warrants. Pre-Funded Warrants [Member] Pre-Funded Warrants Number of warrants or rights outstanding. IFRS Class of Warrant or Right, Outstanding Outstanding, end of year Outstanding, beginning of year Pre-Funded Warrants Number of share options outstanding in share-based payment arrangement Outstanding, end of year Outstanding, beginning of year Number of options outstanding Stock Options Exercise price per share or per unit of warrants or rights outstanding. IFRS Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise price of warrant Per share or per unit amount of equity securities issued. IFRS Shares Issued, Price Per Share Shares issued, price per share The amount of gross proceeds from issuing equity. Gross Proceeds from Issuing Equity Gross proceeds Share issue related cost Costs associated with offering The amount of cash costs for commissions to the agents related to the issuance of shares. Shares Issue, Cash Costs for Commission to Agents Cash costs for commissions to the agents The amount of professional fees and regulatory costs related to the issuance of shares. Shares Issue, Professional Fees and Regulatory Costs Professional fees and regulatory costs The amount of accrued professional fees and regulatory costs related to the issuance of shares. Shares Issue, Accrued Professional Fees and Regulatory Costs Accrued professional and regulatory fees No definition available. Class of Warrant or Right, Roll Forward [Abstract] Number of warrants Number of Pre-Funded Warrants Number of warrants or rights exercised. Class of Warrant or Right, Exercised Exercised Number of warrants or rights issued. Class of Warrant or Right, Issued Issued No definition available. Class of Warrant or Right, Weighted Average Exercise Price [Abstract] Weighted average exercise price Weighted average exercise price of warrants or rights outstanding. Class of Warrant or Right, Outstanding, Weighted Average Exercise Price Outstanding, end of year Outstanding, beginning of year Weighted average exercise price of warrants or rights exercised. Class of Warrant or Right, Exercised, Weighted Average Exercise Price Exercised Weighted average exercise price of warrants or rights issued. Class of Warrant or Right, Issued, Weighted Average Exercise Price Issued Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. IFRS Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Number of shares acquired for each warrant This member stands for warrants excluding pre-funded warrants. Warrants Excluding Pre-Funded Warrants [Member] Warrants excluding pre-funded warrants Number of warrants warrants or rights expired. Class of Warrant or Right, Expired Expired Weighted average exercise price of warrants or rights expired. Class of Warrant or Right, Expired, Weighted Average Exercise Price Expired Number of shares as a percentage of aggregate common shares issued, authorised for issuance under share-based payment arrangement. Percentage Of Shares Authorised For Share Based Payment Arrangement Percentage of shares authorised for issuance Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. IFRS Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Maximum expiry term of stock options Number of share options granted in share-based payment arrangement Granted Number of share options exercised in share-based payment arrangement Exercised The number of share options forfeited and expired in a share-based payment arrangement. Number Of Share Options Forfeited And Expired In Share based Payment Arrangement Forfeited and expired Weighted average exercise price of share options outstanding in share-based payment arrangement Outstanding, end of year Outstanding, beginning of year Weighted average exercise price of options outstanding Weighted average exercise price of share options granted in share-based payment arrangement Granted Weighted average exercise price of share options exercised in share-based payment arrangement Exercised The weighted average exercise price of share options forfeited and expired in a share-based payment arrangement. Weighted Average Exercise Price Of Share Options Forfeited And Expired In Share-Based Payment Arrangement Forfeited and expired Disclosure of range of exercise prices of outstanding share options [table] Ranges of exercise prices for outstanding share options [axis] Ranges of exercise prices for outstanding share options [domain] This member stands for exercise price ranging CA$0.32-$0.50. Exercise Price 0.32 to 0.50 [Member] CA$0.32-$0.50 This member stands for exercise price ranging CA$0.50-$0.66. Exercise Price 0.50 to 0.66 [Member] CA$0.50-$0.66 This member stands for exercise price ranging CA$0.66-$1.80. Exercise Price 0.66 to 1.80 [Member] CA$0.66-$1.80 Disclosure of range of exercise prices of outstanding share options [line items] Stock-based compensation Exercise price of outstanding share options Exercise Prices Weighted average remaining contractual life of outstanding share options Weighted average remaining contractual life Number of share options exercisable in share-based payment arrangement Number of options exercisable Weighted average exercise price of share options exercisable in share-based payment arrangement Weighted average exercise price of options exercisable Option life, share options granted Expected life of stock options Expected volatility, share options granted Expected weighted average volatility Expected dividend as percentage, share options granted Expected dividend yield Risk free interest rate, share options granted Weighted average risk-free interest rate Weighted average fair value at measurement date, share options granted Weighted average fair value of stock options granted in the year Expense from share-based payment transactions Stock-based compensation expense Disclosure of attribution of expenses by nature to their function [table] Attribution of expenses by nature to their function [axis] Attribution of expenses by nature to their function [domain] This member stands for the amount of expense relating to research and development activities of the entity. This member is used to attribute an expense by nature to a functional line item in the statement of profit or loss. Research and Development Expenses [Member] Research and development Selling, general and administrative expense [member] General and administrative Disclosure of attribution of expenses by nature to their function [line items] Operating expenses Short-term employee benefits expense Salaries and management fees Professional fees expense Professional fees The amount of expenditure directly attributable to discovery expenses, recognised in profit or loss. Discovery Expenses Discovery expenses The amount of expenditure directly attributable to preclinical expenses, recognised in profit or loss. Preclinical Expenses Preclinical expenses The amount of expenditure directly attributable to chemistry, manufacturing controls, recognised in profit or loss. Chemistry, Manufacturing Control Expenses Chemistry, manufacturing controls The amount of expenditure directly attributable to clinical expenses, recognised in profit or loss. Clinical Expenses Clinical expenses Miscellaneous other operating expense Other operating expenses Depreciation expense Depreciation Operating expense Operating expenses Schedule disclosing information related to commitments and contingencies. Commitments and Contingencies [Table] Commitments and Contingencies [Table] Maturity [axis] Maturity [domain] Not later than one year [member] Less than 1 year Later than one year and not later than three years [member] 1 -3 years Later than three years and not later than five years [member] 4 - 5 years Later than five years [member] After 5 years Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. Commitments and Contingencies [Line Items] Commitments and contingencies Contractual capital commitments Purchase obligations Scenario [Axis] Scenario [Domain] This member stands for scenario where each time a Licensed Product is the subject of an approved IND. Each Time Licensed Product is Subject of Approved IND [Member] each time a Licensed Product is the subject of an approved IND This member stands for scenario where each time a Licensed Product first enters Phase II human clinical trials. Each Time Licensed Product First Enters Phase II Human Clinical Trials [Member] each time a Licensed Product first enters Phase II human clinical trials This member stands for scenario where each time a Licensed Product first enters Phase III human clinical trials. Each Time Licensed Product First Enters Phase III Human Clinical Trials [Member] each time a Licensed Product first enters Phase III human clinical trials This member stands for scenario where each time a Licensed Product is the subject of a regulatory approval. Each Time Licensed Product is Subject of Regulatory Approval [Member] each time a Licensed Product is the subject of a regulatory approval Represents the royalties as a percentage of net sales in scenario one. Royalties As Percentage Of Net Sales In Scenario One Royalties as a percentage of net sales in scenario one Represents the royalties as a percentage of net sales in scenario two. Royalties As Percentage Of Net Sales In Scenario Two Royalties as a percentage of net sales in scenario two Represents the payments for milestone subject to triggering events. Payments For Milestone Subject To Triggering Events Payments for milestone subject to triggering events Represents the number of payment per new drug candidate. Number of Payment Per New Drug Candidate Number of payment per new drug candidate Represents the percentage of sublicensing income for payments which are subject to triggering events. Percentage of Sublicensing Income For Payments Which are Subject to Triggering Events Percentage of sublicensing income for payments which are subject to triggering events Represents the amount of milestone payments made. Milestone Payments Made Milestone payments made Disclosure of transactions between related parties [table] Categories of related parties [axis] Categories of related parties [domain] This member stands for Bloom Burton Securities Inc, a related party of the entity. Bloom Burton Securities Inc [Member] Bloom Burton Securities Inc This member stands for Mr. William Jarosz, a related party of the entity. Mr. William Jarosz [Member] Mr. William Jarosz Disclosure of transactions between related parties [line items] Related party transactions The amount of commission paid in related party transactions. Commission Paid, Related Party Transactions Commission paid The amount of reimbursement of legal and related fees in related party transactions. Reimbursement Of Legal And Related Fees, Related Party Transactions Reimbursement of legal and related fees Services received, related party transactions Amount paid for consulting services Key management personnel compensation, short-term employee benefits Salaries and management fees Key management personnel compensation, share-based payment Stock-based compensation Key management personnel compensation Total Reconciliation of accounting profit multiplied by applicable tax rates [abstract] Reconciliation of income taxes at statutory rates with the reported taxes Accounting profit Loss before income taxes Applicable tax rate Tax rate Tax expense (income) at applicable tax rate Income tax recovery at statutory rate Tax effect of expense not deductible in determining taxable profit (tax loss) Permanent differences Tax effect from change in tax rate Impact of foreign exchange, foreign tax rates, and changes to tax rates The amount representing the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to share issuance costs and other timing differences. Tax Effect of Share Issuance Costs and Other Timing Differences Share issuance costs and other timing differences The amount representing the ddjustment to prior years provision versus statutory tax returns. Tax Effect of Adjustment To Provision Versus Statutory Tax Returns Adjustment to prior years provision versus statutory tax returns The amount representing the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to income tax benefit not recognized. Tax Effect of Income Tax Benefit Not Recognized Income tax benefit not recognized Disclosure of temporary difference, unused tax losses and unused tax credits [table] Temporary difference, unused tax losses and unused tax credits [axis] Temporary difference, unused tax losses and unused tax credits [domain] Unused tax losses [member] Non-capital loss carry forwards This member stands for share issuance costs and other. Share Issuance Costs And Other [Member] Share issuance costs and other This member stands for intangible assets. Intangible Assets [Member] Intangible assets This member stands for research and development costs. Research And Development Costs [Member] Research and development costs Unused tax credits [member] Non-refundable R&D tax credits Disclosure of temporary difference, unused tax losses and unused tax credits [line items] Income taxes Deductible temporary differences for which no deferred tax asset is recognised Temporary differences not been recognized Disclosure of geographical areas [table] Geographical areas [axis] Geographical areas [domain] CANADA Canada AUSTRALIA Australia Disclosure of geographical areas [line items] Income taxes Segmented information Unused tax losses for which no deferred tax asset recognised Non-capital loss carry forward expiration UNITED STATES USA Represents the number of geographical areas in which company operates. Number of Geographical Areas in Which Company Operates Number of geographical areas in which company operates Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [table] Classes of financial instruments [axis] Classes of financial instruments [domain] This member stands for receivables. Receivables [Member] Outstanding receivables Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] Carrying amount [member] Accumulated impairment [member] Expected credit losses Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] Disclosure of reconciliation of changes in loss allowance and explanation of changes in gross carrying amount for financial instruments [line items] Financial assets Financial assets Disclosure of nature and extent of risks arising from financial instruments [table] This member stands for cash and cash equivalents. ifrs Cash and Cash Equivalents [Member] Cash and cash equivalents This member stands for short-term investments. ifrs Short-term Investments [Member] Short-term investments This member stands for accounts payable and accrued liabilities. ifrs Accounts Payable and Accrued Liabilities [Member] Accounts payable and accrued liabilities Currency [Axis] All Currencies [Domain] United States of America, Dollars US Australia, Dollars Australian Euro Member Countries, Euro Euro Canada, Dollars Canadian Disclosure of nature and extent of risks arising from financial instruments [line items] Financial instruments and risk management Risk exposure associated with instruments sharing characteristic Balances held in foreign currencies The reasonably possible percentage of the increase in the designated risk component used to determine the value of the financial instrument. Excludes defined benefit plan obligations. Percentage of Reasonably Possible Increase in Risk Assumption Percentage of reasonably possible increase in risk assumption The increase (decrease) in profit (loss) and comprehensive income (loss) as a result of an increase in a designated risk component that was reasonably possible at the end of the reporting period. Excludes defined benefit plan obligations. Increase (Decrease) in Loss and Comprehensive Loss Due to Reasonably Possible Increase in Designated Risk Component Increase (decrease) in loss and comprehensive loss due to reasonably possible increase in designated risk component The reasonably possible percentage of the decrease in the designated risk component used to determine the value of the financial instrument. Excludes defined benefit plan obligations. Percentage of Reasonably Possible Decrease in Risk Assumption Percentage of reasonably possible decrease in risk assumption The increase (decrease) in profit (loss) and comprehensive income (loss) as a result of an increase in a designated risk component that was reasonably possible at the end of the reporting period. Excludes defined benefit plan obligations. Increase (Decrease) in Loss and Comprehensive Loss Due to Reasonably Possible Decrease in Designated Risk Component Increase (decrease) in loss and comprehensive loss due to reasonably possible increase in designated risk component Disclosure of non-adjusting events after reporting period [table] This member stands for commitment milestone payments. Commitments Milestone Payments [Member] Milestone payment Disclosure of non-adjusting events after reporting period [line items] Subsequent events Schedule disclosing information related to change in presentation currency. Disclosure of Change in Presentation Currency [Table] Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. Disclosure of Change in Presentation Currency [Line Items] Change in presentation currency Profit (loss) [abstract] Income statement